NEW YORK (GenomeWeb) – Natera today announced it has raised $55.5 million in a private round of financing to expand its sales and marketing operations, as well as its R&D.
Sofinnova Ventures led the financing and were joined by Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners, and OrbiMed Advisors.
The financing will go toward the development of existing products such as Natera's Panorama non-invasive prenatal test, the development of non-invasive cell-free DNA-based tests for the early detection and therapeutic monitoring of cancer, and clinical trials to demonstrate the utility of its tests in clinical practice, the San Carlos, Calif.-based firm said.
In conjunction with the financing, James Healy, a general partner at Sofinnova, has joined Natera's board.
The company previously raised $54.6 million in the spring of 2013.